POSB109 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin with Bendamustine and Rituximab vs. Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.382
https://www.valueinhealthjournal.com/article/S1098-3015(21)02177-X/fulltext
Title :
POSB109 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin with Bendamustine and Rituximab vs. Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02177-X&doi=10.1016/j.jval.2021.11.382
First page :
Section Title :
Open access? :
No
Section Order :
11160